FinTrust Capital Advisors’s Emergent Biosolutions EBS Stock Holding History

FinTrust Capital Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,300	Closed	-$261K	–	1151
2020 Q2	$261K	Sell	3,300 -6,396	-66%	-$477K	0.1%	167
2020 Q1	$562K	Buy	+9,696	New	+$559K	0.27%	76
2019 Q1	–	Sell	-500	Closed	-$30K	–	1273
2018 Q4	$30K	Buy	+500	New	+$32.2K	0.01%	482

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

FinTrust Capital Advisors's EBS Position: Q3 2020 in Review

FinTrust Capital Advisors sold out of Emergent Biosolutions (EBS) in Q3 2020, closing a stake of 3,300 shares — an estimated $261K sold.

FinTrust Capital Advisors first reported a position in EBS in Q4 2018 and held it in 3 quarters. The position peaked at $562K in Q1 2020. 358 funds tracked by Wall St. Rank hold EBS as of Q3 2020.

FinTrust Capital Advisors reported no remaining Emergent Biosolutions position as of Q3 2020 after selling out during the quarter.
FinTrust Capital Advisors sold 3,300 Emergent Biosolutions shares in Q3 2020, an estimated $261K.
FinTrust Capital Advisors first reported a position in Emergent Biosolutions in Q4 2018 and held it in 3 quarters.
FinTrust Capital Advisors's Emergent Biosolutions position peaked at $562K in Q1 2020.
358 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2020.

Based on FinTrust Capital Advisors's 13F filing for Q3 2020, filed 10 Nov 2020.